Drug-coated balloons or drug-eluting stents: Determining an optimum strategy for the high bleeding risk patients by Corballis, Natasha H. et al.
 1 
 
Drug coated balloons or drug eluting stents: determining an optimum strategy for the high 
bleeding risk patients 
Natasha H Corballis1, 2, MBBS, MRCP; Tha H Nyi 3, Vassilios S Vassiliou 1,2 *# MA, MBBS, PhD, 
FESC, FACC, FRCP; Simon C Eccleshall1#MBChB, MRCP, MD  
 
# Contributed equally 
 
1 Department of Cardiology, Norfolk and Norwich University Hospital NHS Foundation Trust, 
Colney Lane, Norwich, UK, NR4 7LJ, UK 
 
2 Norwich Medical School, University of East Anglia, Bob Champion Research and Education, 
James Watson Road, NR4 7UQ, UK 
 
3 Department of Acute Medicine, Norfolk and Norwich University Hospital NHS Foundation 
Trust, Colney Lane, Norwich, UK, NR4 7UY, UK 
 
*Corresponding author: 
Dr Simon C Eccleshall 
Department of Cardiology 
Norfolk and Norwich University Hospital NHS Foundation Trust 
Norwich NR4 7UY 
United Kingdom 




Dr Natasha Corballis and Dr Tha H Nyi have no conflicts of interests to declare.  
Dr Vassilios Vassiliou reports speaker fees from Medtronic and Daichii-Sankyo. 






The management of patients who require percutaneous coronary intervention and are at 
high risk of bleeding continues to be challenging; balancing thrombotic versus bleeding risk 
to determine the safest duration of dual antiplatelet (DAPT).  
 
With recent efforts to determine safety in one-month duration of dual antiplatelet therapy 
after implantation of a drug eluting stent (DES), alternative strategies such as drug coated 
balloons (DCB) have also been explored as both have been shown superior to bare metal 
stent (BMS) which has historically been used for high bleeding risk patients.  
 
We sought to review the literature surrounding safety profile and bleeding events with both 
DCB and DES and conclude whilst DCB and DES offer safety of cessation of DAPT after one-
month,  DCBs offer lower MACE events after one-month duration of DAPT.  




Coronary artery disease is the leading cause of morbidity and mortality globally 1. Dual 
antiplatelet therapy (DAPT) in the form of aspirin and a P2Y12 inhibitor is the mainstay of 
pharmacotherapeutic treatment for an acute coronary syndrome (ACS) and prevention of 
stent thrombosis after PCI for ACS or stable coronary disease. DAPT with ticlopidine plus 
aspirin was first shown to be superior to anticoagulation and aspirin for patients undergoing 
percutaneous coronary intervention (PCI) in 1996 2. Subsequently, DAPT (clopidogrel plus 
aspirin) has been shown to be superior to aspirin alone with a relative risk reduction of 
26.9% of major adverse cardiovascular outcomes (MACE) 3. DAPT has since become one of 
the most extensively investigated treatment strategies in cardiology with over 35 RCTs and 
225,000 patients and is increasingly important given the volume of patients requiring DAPT. 
In 2015 European based population estimates suggested that 1.4-2.2 million patients 
require DAPT per year 1.  
 
The duration of DAPT has evolved with the introduction of second and now third generation 
drug eluting stents. The first-generation drug eluting stents raised the concern of very late 
stent thrombosis after one year4  with evidence supporting a prolonged duration of DAPT 
preventing subsequent spontaneous myocardial infarction (MI) 5 and led to RCTs 
investigating prolonged duration of DAPT. The trade-off of reducing ischaemic sequelae is 
always balanced with the risk of bleeding with evidence supporting a significant increase in 
bleeding events with greater than twelve months of DAPT with minimal reduction in MACE 





Identifying bleeding risk/ risk stratification 
Given the aging population with increasingly complex co-morbidities that we are seeing, the 
risk of bleeding is greater. This has led to the introduction of bleeding risk stratification 
scoring systems both for clinical and research purposes. Both the DAPT 7 and PARIS 8 risk 
stratification scores were introduced based on prediction of events during the index 
admission or shortly after. Neither of these looked at the duration of DAPT in relation to 
bleeding risk. The most comprehensive scoring system to date is the PRECISE-DAPT scoring 
system and is recommended in the European Society of Cardiology (ESC) guidelines as a IIb 
A recommendation for use 1. The PRECISE-DAPT study showed that if patients considered at 
a high risk of bleeding were given a prolonged (> 12 months) duration of DAPT, there was no 
ischaemic benefit but a significantly higher bleeding risk with a number needed to harm 
(NNH) of 38 9. 
 
Guidelines 
DAPT guidelines are different for ACS as opposed to PCI in stable coronary disease. 
Regardless of bleeding risk, DAPT is recommended for 12 months for all patients after an 
ACS 1.  
However, for patients undergoing PCI for stable coronary disease, the evidence is less 
cohesive. This becomes relevant for two reasons:  
- As a stable group, there is time to plan the intervention strategy, assess bleeding risk 
and determine an appropriate approach to an individual patient  
- There is less clear-cut evidence on the duration of DAPT for this cohort 
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The current ESC guidelines for stable coronary disease and DAPT (shown in Figure 1) advise 
that for stable coronary disease treated with DES/BMS or DCB, for patients not at a high risk 
of bleeding, a 6-month duration of DAPT comes with a Class I A recommendation with a 
class IIb A recommendation to continue DAPT for a further 6 months (DAPT consisting of 
aspirin and clopidogrel). For patients at a high risk of bleeding treated with DES/ BMS or 
DCB, a one-month duration of DAPT has a Class IIb C recommendation with 3-months of 
DAPT having a class IIa B recommendation. 
 
Figure 1: The ESC recommendations for DAPT after PCI for stable coronary disease 
 




Despite these guidelines, routine clinical practice remains giving a 12-month duration of 
DAPT for patients receiving a DES for stable coronary disease unless there are significant 
bleeding sequelae 10.  
 
A systematic review and meta-analysis (17 studies, 46 864 patients) compared short-term ( 
6-months but excluded those with  one-month) with standard duration of DAPT (12 
months) and long duration DAPT (12 months) for drug eluting stents. This included all 
patients with ACS and stable coronary disease. It showed a statistically significant increase 
in all-cause mortality and major bleeding in the long duration DAPT group  and an increase 
in any bleeding in standard duration DAPT as compared to short-term duration DAPT with 
no statistically significant difference in major adverse cardiovascular outcomes (MACE) 11. 
This indicates a safety in 6-month duration of DAPT but for those patients who may benefit 
from a shorter duration again, the evidence is less clear. This also did not identify whether 
patients were at a higher risk of bleeding.  
  
Drug coated balloons: a practical alternative  
Drug-coated balloons (DCB) are an attractive proposition for cardiology interventionalists 
who subscribe to the “leave nothing behind”  philosophy 12. The use of DCBs are currently 
recommended in ESC guidelines for small vessel disease and in-stent restenosis. However, 
over the past two years, the evidence supporting the role of DCBs in wider circumstances 
has increased 13–16.  
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One significant benefit of a DCB strategy is the proposed shorter duration of DAPT required. 
Previous consensus groups have all recommended a one-month duration of DAPT for stable 
coronary disease 17–19. This recommendation was changed by the 2017 ESC Focused DAPT 
Update, which recommended a 6-month duration of DAPT after DCB angioplasty 1. In 
response to this, we interrogated our registry database of a large, real world population. We 
reported 303 patients treated with one-month DAPT after elective DCB angioplasty, with no 
occurrence of major adverse cardiovascular events (MACE)  at six-months and found that 
one-month duration of DAPT appears safe after DCB angioplasty for stable coronary 
disease20. 
 
Figure 2: A visual representation of the role of DCBs, their indication for use and evidence 
supporting their use in de novo coronary disease.  
 
Having established the safety of one-month duration after DCB angioplasty in stable 
coronary disease, we sought to review the evidence for shorter duration DAPT in terms of 
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bleeding rates, clinical outcomes and safety profiles for both DCB and DES. Table 1 provides 
a summary of all papers included in the review.  
Table 1: Summary of all randomised controlled trials included in discussion 
Where DES= drug eluting stent, BMS= bare metal stent, n=number of participants, MACE= major adverse 
cardiovascular outcomes, CD= cardiac death, MI= myocardial infarction, ST= stent thrombosis, TVR= target 
vessel revascularisation, TLR= target lesion revascularisation 
 
 
DES with one-month duration of DAPT with improved safety profile    
Study name Experimental arm Control arm  Study population Primary outcome 
DES:     
LEADERS-FREE 21 2nd generation DES BMS n=2466 
ACS & stable coronary 
disease (high bleeding 
risk) 
 
MACE (CD, MI, ST) at 390 
days 
ZEUS 22 2nd generation DES BMS n=1606  
ACS & stable coronary 
disease (high bleeding 
risk, high thrombotic risk 
or low restenosis risk) 
 
MACE (all-cause mortality, 
MI, TVR) at 12 months  
SENIOR 23 2nd generation DES BMS n=1200 >75 ACS & stable 
angina 
MACE (all-cause mortality, 
stroke, MI, TLR) at 12 
months  
 





ACS & stable coronary 
disease (high bleeding 
risk) 
 
MACE (CD, MI, ST) at 12 
months  
STOP-DAPT2 25 DES with one-
month DAPT 
DES with 12 
months DAPT 
n=3045 
ACS & stable coronary 
disease 
Combined cardiovascular 
and bleeding composite 
endpoint 
 
DCB:     
DEBUT 15 DCB BMS n=208 
ACS & stable coronary 
disease (high bleeding 
risk) 
 
MACE (CD, MI, TLR) 
Basket-Small 2 13 DCB DES n=758 ACS & stable 
coronary disease (one-
month DAPT only in 
stable group) 
 
MACE (CD, MI, TVR) at 12 
months  
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There has been recent emphasis on identifying safety in one month duration of DAPT for 
DES given that studies suggest at least 15% of patients undergoing PCI are at high risk of 
bleeding 26. Until recently, bare metal stents (BMS) were considered an appropriate strategy 
for patients at a high risk of bleeding as a one-month duration was deemed safe and 
adequate. This was despite all of the evidence showing superiority of DES compared to BMS, 
particularly in terms of target lesion revascularisation 27. In addition, there had been no 
safety/ efficacy data supporting the use of DES for one-month only. As such, significant 
advancements have been made in stent technology in improving safety profile for a shorter 
duration of DAPT. This includes newer generation DES, bioresorbable polymer and faster re-
endothelization combined with thinner struts which all influence rates of stent thrombosis 
28. Subsequently, the LEADERS-FREE, ZEUS and SENIOR trials all changed perspective on this 
as showing that DES was superior in terms of safety and efficacy over BMS with one-month 
duration of DAPT 22,23,29. LEADERS-FREE randomised 2466 patients, including those with ACS 
and stable coronary disease, to either second generation DES or BMS with one-month 
duration of DAPT. A primary safety end point of cardiac death, MI or stent thrombosis 
showed DES to be superior to BMS (9.4% v 12.9%, HR: 0.71(0.56-0.91), p=0.005). There was 
no statistical significance between bleeding events of BARC 3-5 (7.2v7.3%, p=0.96). 29 
The ZEUS study compared second generation DES with BMS in a more heterogeneous 
population- those at high bleeding risk, high thrombotic risk or low restenosis risk. A 
subgroup analysis of patients at a high bleeding risk (828) favoured DES over BMS with a 
primary composite outcome of death, MI or TVR (HR: 0.74 (0.57-0.97)). 22  
 
The SENIOR trial randomised 1200 patients over the age of 75 to either DES or BMS and 
gave a one-month duration of DAPT for stable angina and six months for ACS. Although 
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these patients were not specifically at high risk of bleeding, their age does contribute to 
bleeding risk. The primary endpoint was a composite of all-cause mortality, MI, stroke or 
ischaemia driven TLR and results favoured DES (12% v 16%, RR: 0.71 (CI: 0.52-0.94), p=0.02). 
Bleeding complications occurred in 5% of both arms. 23 
 
These three studies have shown superiority of DES over BMS in patients at high risk of 
bleeding who would benefit from a shorter duration of DAPT. Having identified that DES is 
superior to BMS in this situation, further studies have sought to evaluate safety of one-
month duration of DAPT compared to a longer duration.  
 
The more recent ONYX One trial comparing the Onyx Zotorolimus eluting stent with the 
biofreedom stent showed non-inferiority with one-month duration of DAPT, although, event 
rates were notably high with primary composite safety end point (cardiac death, MI, ST) at 
one year of 17.1% v 16.9% 30. 
 
STOP-DAPT 2 randomised 3045 patients in Japan to either one-month or one-year DAPT 
after PCI (of which 38% were ACS). A primary composite endpoint of cardiovascular and 
bleeding events (cardiac death, MI, definite ST, ischaemic or haemorrhagic stroke or TIMI 
major or minor bleeding) showed superiority of one-month DAPT (2.36% v 3.7%, HR:0.64 
(0.42-0.98), p=0.04) 25. Of note, the majority of patients were low to intermediate risk of 
bleeding. 
 
DCBs and one-month duration DAPT 
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Two prospective studies have been conducted reporting cardiovascular outcomes and 
bleeding events using DCB in one arm.   
The first study, the DEBUT trial, was a randomised control trial comparing bare metal stent 
(BMS) with DCB in patients at high risk of bleeding. This included patients with stable 
coronary disease or ACS in the form of NSTEMI/ unstable angina but excluded STEMI. The 
occurrence of a primary outcome of MACE in stable angina was 0% in DCB v 11% (HR: 0.35, 
95%CI: 0.11-1.09, p=0.069). DEBUT also reported a 13% bleeding rate at 9-months in DCB 
patients with 11% in BMS group (p=0.59). This was in a high-risk of bleeding cohort with 
58% (DCB cohort) on an oral anticoagulant and 29% (DCB cohort) anaemic with additional 
risk factors for bleeding including old age (>80 years old), CKD3 or more, thrombocytopenia, 
frailty, synthetic liver dysfunction and previous ICH or CVA 15. 
 
The second study was the BASKET-Small 2 trial 13. This was an RCT comparing DES with DCB 
for small vessel disease in patients with ACS and stable coronary disease in which 758 
patients were randomised to either DCB or DES, powered to detect non-inferiority in DCB. 
The patients who received DCB for stable coronary disease were given a one-month 
duration of DAPT and those who had an ACS were given 12 months. The majority of patients 
included were those with stable coronary disease (70% in the DCB patients and 73% in the 
DES patients). Risk of bleeding criteria were not specified in the patient cohort. MACE 
events at 12 months were 7.3% in the DCB v 7.5% in the DES arm (0·97, 0·58–1·64; 
p=0·9180). Major bleeding rates were low, at 1.1 v 2.4% with a p-value of 0.46. The lower 
rates occurred in the DCB cohort but this was not of statistical significance 13.  
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Finally, our own retrospective database analysis of all patients receiving one-month 
duration of DAPT showing no occurrence of MACE at six months further strengthens the 
safety argument for the use of DCBs in those at high risk of bleeding 20. 
 
Whilst the current ESC guidelines recommend DCB only for small vessel disease and in-stent 
restenosis31, there is an increasing body of evidence supporting the use of DCBs in large 
vessels 32,33. With upcoming RCTs to further investigate the use of DCBs in large vessels, 
their role in high bleeding risk patients is thought to increase.  
 
Acute Coronary Syndromes and duration of DAPT  
The current guidelines still recommend a 12 month duration of DAPT for all ACS patients, 
regardless of treatment strategy 1. Although the purpose of this review is to focus  on stable 
coronary disease, it is worth briefly mentioning the evidence for DCB and DES for ACS one-
month DAPT. Within the DES RCTs, ACS patients made up a significant proportion of the 
numbers: 41% in LEADERS-FREE 21, 63% in ZEUS 22, 46% in SENIOR 23, 52% in ONYX-ONE 24 
and 38% in STOP-DAPT 2 24. In comparison, the only data for one-month DAPT in DCB in ACS 
is in DEBUT, where ACS patients account for 46% of patients 15 BASKET-SMALL 2 gave a 12 
month duration of DAPT to all ACS patients. Therefore, although the clinical outcomes in 
DEBUT are excellent for DCB, there is currently a smaller body of evidence supporting the 
use of one-month DAPT in ACS patients with DCB.  
 
Discussion 
When comparing the DEBUT data (DCB) with the LEADERS-FREE trial29 (DES v BMS in high 
risk bleeding patients), the DEBUT bleeding rates reported are not as high as those reported 
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in the LEADERS-FREE trial, where bleeding events (BARC 1-5) were 18.1 v 19.1% (DES v BMS) 
compared to 13 v 11% in DEBUT. Although the DEBUT numbers are smaller, both studies are 
looking at high risk of bleeding. In comparison, the BASKET-Small 2 trial reported lower 
bleeding events at 4 v 9% (DCB v DES) but this patient group was not identified as being at a 
higher risk of bleeding, which may explain the lower bleeding rates.  
 
Of particular interest however is the fact that although the bleeding rates were slightly 
lower in DEBUT compared to LEADERS-FREE, the MACE rates were significantly lower in the 
DEBUT trial (1% for DCB) than both the LEADERS-FREE trial (9.4%) and the Onyx One trial 
(17.1% for the Zotorolimus eluting stent) 24. Of course, these MACE rates cannot be directly 
compared, however it certainly adds strength to the concept that DCB is a very appealing 
strategy for patients at high risk of bleeding. This is backed up by our registry data with 0% 
MACE rates at 6-months in patients who received one-month of DAPT 20.  
 
Where the LEADERS-FREE, SENIOR and ONYX-ONE all report high MACE occurrence in the 
DES arm (9.4%, 12% and 17.1%), the results of the Japanese STOP-DAPT 2 were significantly 
lower with MACE rates at 2.36%. One hypothesis for this could be the use of intracoronary 
imaging to optimise stent sizing in almost all patients, which is not standard western 
practice.  
With the exception of the STOP-DAPT 2 trial, DCB studies show a significantly lower MACE 
rate when compared with DES or BMS. This adds weight to the argument that DCB is an 
attractive proposition for patients who are at a higher risk of bleeding, particularly in the 
stable angina cohort where bleeding risk can be assessed pre-procedure and angioplasty 




Whilst all of the included DES studies have been conducted with large numbers, the sample 
size in DEBUT and Basket-Small 2 is smaller although both studies were adequately powered 
to answer their primary outcome. As the population in all of the included studies vary from 
those at high risk of bleeding to a heterogeneous cohort, no definitive subgroup meta-
analysis can be conducted that would add any weight to the available data.  
 
Conclusion 
In conclusion, we are increasingly faced with a more complex patient cohort with higher risk 
of bleeding associated with DAPT. Although it is clear that a 6-month duration of DAPT can 
be given with adequate effects on MACE with DES, the MACE rates remain high with only 
one-month of DAPT in the DES RCTs. In comparison, a one-month duration of DAPT with 
DCB in the DEBUT study and our own series shows significantly lower MACE rates than the 
contemporaneous DES studies. This strengthens the viewpoint that DCB is a very attractive 
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